KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Interest Expenses (2016 - 2023)

Historic Interest Expenses for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q2 2023 value amounting to $910000.0.

  • Supernus Pharmaceuticals' Interest Expenses fell 4972.38% to $910000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $910000.0, marking a year-over-year decrease of 8628.07%. This contributed to the annual value of $2.4 million for FY2023, which is 6584.16% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Interest Expenses of $910000.0 as of Q2 2023, which was down 4972.38% from $1.5 million recorded in Q1 2023.
  • Supernus Pharmaceuticals' 5-year Interest Expenses high stood at $6.1 million for Q1 2021, and its period low was $910000.0 during Q2 2023.
  • Moreover, its 5-year median value for Interest Expenses was $5.7 million (2019), whereas its average is $4.4 million.
  • In the last 5 years, Supernus Pharmaceuticals' Interest Expenses surged by 71868.9% in 2019 and then plummeted by 7313.78% in 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Interest Expenses (Quarter) stood at $5.8 million in 2019, then grew by 5.52% to $6.1 million in 2020, then decreased by 2.66% to $5.9 million in 2021, then crashed by 73.14% to $1.6 million in 2022, then crashed by 42.91% to $910000.0 in 2023.
  • Its Interest Expenses was $910000.0 in Q2 2023, compared to $1.5 million in Q1 2023 and $1.6 million in Q4 2022.